EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Immunogenicity, Safety and Immune Persistence of Sabin Strain Inactivated Poliovirus Vaccine: A Phase III Clinical Trial

Teng Huang, Cong Wu iD, Zhifang Ying, Zhongyang Zhang, Qingliang Li, Weiwei Lu, Gang Yu, Pengliang Hao, Shiyi Liu, Huijie Guo, Junhui Tao, Yujuan Yang und 4 weitere

Scandinavian Journal of Immunology · 2026

DOI: 10.1111/sji.70097 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Scandinavian Journal of Immunology, 2026. Verfasst von Teng Huang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Vaccine Clinical Research, Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, China. Hauptthemen laut MEDLINE: Poliovirus Vaccine, Inactivated, Poliomyelitis, Immunogenicity, Vaccine, Poliovirus. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Wuhan Institute of Biological Products Co.,Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The phased transition from oral poliovirus vaccine (OPV) to full‐course immunisation with inactivated poliovirus vaccine (IPV) is a critical strategy for the global eradication of poliomyelitis. A randomised, double‐blind, multi‐centre, active‐controlled clinical trial was conducted among healthy infants in China to evaluate the immunogenicity and safety of the Sabin strain IPV (sIPV). A total of 1260 healthy 2‐month‐old infants who had not previously received poliovirus vaccination were randomly assigned to receive three doses of either the investigational vaccine (sIPV) or the control vaccine (wIPV) according to a 0‐, 28‐ and 56‐day schedule, followed by a booster dose at 18 months of age. Per‐protocol analysis (sIPV: n = 563; wIPV: n = 561) showed postprimary seroconversion rates for sIPV versus wIPV were: Type 1 (97.69% vs. 94.65%), Type 2 (98.22% vs. 87.70%) and Type 3 (99.82% vs. 98.57%). sIPV met noninferiority criteria (margin: −5%) for all serotypes, with one‐sided 97.5% CI lower limits exceeding this margin. Postbooster geometric mean titre (GMT) for sIPV were 7297.40 (Type 1), 8490.51 (Type 2) and 7158.27 (Type 3), indicating robust immune memory. Safety profiles were similar overall, though sIPV had higher incidences of fever and hypersensitivity reactions. Serious adverse event rates were comparable (sIPV: 2.86% vs. wIPV: 2.70%). The study confirms sIPV's immunogenicity is noninferior to wIPV, with a potent booster response and acceptable safety. The trial was registered with chinadrugtrials.org.cn (CTR20170648).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poliovirus Vaccine, InactivatedPoliomyelitisImmunogenicity, VaccinePoliovirusPoliovirus Vaccine, OralHumansFemaleInfantAntibodies, ViralMaleDouble-Blind MethodChinaVaccinationImmunization ScheduleImmunization, Secondary

Stichwörter der Autor:innen

Sabin strainantibody persistenceinactivated vaccinephase 3 trialpoliovirus

Substanzen

Poliovirus Vaccine, InactivatedAntibodies, ViralPoliovirus Vaccine, Oral

Autor:innen und Institutionen

  • Institute of Vaccine Clinical Research, Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, China.
  • National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co., Ltd, Wuhan, China.
  • National Institutes for Food and Drug Control, Beijing, China.
  • Department of Research and Development, National Vaccine and Serum Institute, Beijing, China.
  • Liujiang County Center for Disease Control and Prevention, Liuzhou, China.
  • Sanjiang Dong Autonomous County Center for Disease Control and Prevention, Liuzhou, China.

ORCID-Profile: Cong Wu, Jiayou Zhang, Xiuling Li

Förderung

  • Wuhan Institute of Biological Products Co.,Ltd

Zitieren

APA

Huang, T., Wu, C., Ying, Z., Zhang, Z., Li, Q., Lu, W., Yu, G., Hao, P., Liu, S., Guo, H., Tao, J., Yang, Y., Tao, C., Chen, W., Zhang, J., & Li, X. (2026). Immunogenicity, Safety and Immune Persistence of Sabin Strain Inactivated Poliovirus Vaccine: A Phase III Clinical Trial. Scandinavian Journal of Immunology. https://doi.org/10.1111/sji.70097

Vancouver

Huang T, Wu C, Ying Z, Zhang Z, Li Q, Lu W, et al. Immunogenicity, Safety and Immune Persistence of Sabin Strain Inactivated Poliovirus Vaccine: A Phase III Clinical Trial. Scandinavian Journal of Immunology. 2026. doi:10.1111/sji.70097

BibTeX
@article{Huang2026,
  author = {Huang, Teng and Wu, Cong and Ying, Zhifang and Zhang, Zhongyang and Li, Qingliang and Lu, Weiwei and Yu, Gang and Hao, Pengliang and Liu, Shiyi and Guo, Huijie and Tao, Junhui and Yang, Yujuan and Tao, Chencai and Chen, Wei and Zhang, Jiayou and Li, Xiuling},
  title = {Immunogenicity, Safety and Immune Persistence of Sabin Strain Inactivated Poliovirus Vaccine: A Phase III Clinical Trial},
  journal = {Scandinavian Journal of Immunology},
  year = {2026},
  doi = {10.1111/sji.70097}
}
Kostenlos starten →